Spheroids reveal hypoxia‑driven spatial restriction of adenoviral infection

Read full text
Authors: Tamara Büttner, Xiaoyan Wang, Brenda Krishnacoumar, Athanasios Papadamakis, Suna Cicek, Yves Schild, Sandra Winning, Elisabeth Littwitz-Salomon, Anja Ehrhardt, Ulf Dittmer, Wibke Bayer, Joachim Fandrey
+1 more Anna Malyshkina
Cited by: 1
References: 44

Abstract

Hypoxia is a hallmark of solid tumors and represents a major barrier for effective cancer therapies, including oncolytic virotherapy. While adenoviruses are widely studied as oncolytic agents, the impact of tumor-associated hypoxia on viral infection and spatial spread remains incompletely understood. Here, we investigated how oxygen availability influences adenovirus infection in two-dimensional (2D) cultures and three-dimensional (3D) tumor spheroids. We confirmed that cell lines commonly used in adenovirus research (HEK293A, A549), as well as KP4 pancreatic cancer cells, exhibited a physiological response to hypoxia. In KP4 monolayers, hypoxia strongly reduced adenoviral protein production. To model oxygen gradients found in solid tumors, we established stable KP4 spheroids and performed spatial analysis of HAdV5_GFP infection. When virus was added during spheroid formation and hypoxia development, infection was largely restricted to the well-oxygenated outer rim. In contrast, inoculation of virus under normoxia prior to spheroid formation resulted in a more uniform distribution of infected cells throughout the spheroid. Together, our findings demonstrate that hypoxia not only suppresses adenoviral replication in cell culture but also shapes the spatial pattern of infection in 3D tumor models, highlighting the importance of hypoxia-relevant 3D systems in preclinical evaluation of oncolytic adenoviruses.

Fields of Study & Subjects

Virus-based gene therapy research Cancer Research and Treatments Cancer Hypoxia and Metabolism

Publication details

Journal / source
Scientific Reports
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
21 May 2026
Language
EN